

Ryotaro Nakamura

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6741421/publications.pdf>

Version: 2024-02-01

185
papers

5,418
citations

94433

37
h-index

95266

68
g-index

187
all docs

187
docs citations

187
times ranked

5779
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. <i>Blood</i> , 2015, 126, 1033-1040. | 1.4 | 565 |
| 2 | Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. <i>Blood</i> , 2017, 130, 2243-2250. | 1.4 | 352 |
| 3 | Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cellâ€“Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide. <i>Journal of Clinical Oncology</i> , 2017, 35, 3002-3009. | 1.6 | 255 |
| 4 | PD-1 blockade for relapsed lymphoma postâ€“allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. <i>Blood</i> , 2017, 130, 221-228. | 1.4 | 214 |
| 5 | Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. <i>Haematologica</i> , 2018, 103, e404-e407. | 3.5 | 212 |
| 6 | Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. <i>Blood</i> , 2014, 124, 1372-1377. | 1.4 | 178 |
| 7 | An early-biomarker algorithm predicts lethal graft-versus-host disease and survival. <i>JCI Insight</i> , 2017, 2, e89798. | 5.0 | 166 |
| 8 | Hematopoietic Stem-Cell Transplantation for Advanced Systemic Mastocytosis. <i>Journal of Clinical Oncology</i> , 2014, 32, 3264-3274. | 1.6 | 146 |
| 9 | MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. <i>Blood</i> , 2018, 131, 2846-2855. | 1.4 | 140 |
| 10 | Thrombotic Microangiopathy Associated with Sirolimus Level after Allogeneic Hematopoietic Cell Transplantation with Tacrolimus/Sirolimus-Based Graft-versus-Host Diseaseâ€“Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 298-304. | 2.0 | 100 |
| 11 | A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens. <i>Blood</i> , 2010, 115, 1098-1105. | 1.4 | 99 |
| 12 | Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). <i>Blood</i> , 2013, 122, 1974-1982. | 1.4 | 92 |
| 13 | Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. <i>Blood</i> , 2014, 124, 3221-3227. | 1.4 | 92 |
| 14 | Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. <i>Blood Advances</i> , 2019, 3, 1826-1836. | 5.2 | 89 |
| 15 | Clinical Evaluation of Safety and Immunogenicity of PADRE-Cytomegalovirus (CMV) and Tetanus-CMV Fusion Peptide Vaccines With or Without PF03512676 Adjuvant. <i>Journal of Infectious Diseases</i> , 2012, 205, 1294-1304. | 4.0 | 86 |
| 16 | The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1322-1340. | 2.0 | 85 |
| 17 | Phase I Trial of Total Marrow and Lymphoid Irradiation Transplantation Conditioning in Patients with Relapsed/Refractory Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 618-624. | 2.0 | 84 |
| 18 | Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1348-1356. | 2.0 | 76 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2021, 39, 3328-3339. | 1.6 | 72 |
| 20 | MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults. <i>Blood</i> , 2017, 129, 114-125. | 1.4 | 69 |
| 21 | Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial. <i>Lancet Haematology</i> , 2016, 3, e87-e98. | 4.6 | 67 |
| 22 | Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 2 dose de-escalation study. <i>Lancet Haematology</i> , 2015, 2, e367-e375. | 4.6 | 64 |
| 23 | Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2002-2007. | 2.0 | 64 |
| 24 | Impact of Graft Cell Dose on Transplant Outcomes following Unrelated Donor Allogeneic Peripheral Blood Stem Cell Transplantation: Higher CD34+ Cell Doses Are Associated with Decreased Relapse Rates. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 449-457. | 2.0 | 63 |
| 25 | Survival following allogeneic transplant in patients with myelofibrosis. <i>Blood Advances</i> , 2020, 4, 1965-1973. | 5.2 | 63 |
| 26 | Safety and Tolerability of SARS-CoV2 Emergency-Use Authorized Vaccines for Allogeneic Hematopoietic Stem Cell Transplant Recipients. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 938.e1-938.e6. | 1.2 | 63 |
| 27 | Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. <i>American Journal of Hematology</i> , 2019, 94, E253-E255. | 4.1 | 62 |
| 28 | Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 265-269. | 2.0 | 62 |
| 29 | Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents. <i>Blood Advances</i> , 2019, 3, 4043-4049. | 5.2 | 55 |
| 30 | Prediction of cardiovascular disease among hematopoietic cell transplantation survivors. <i>Blood Advances</i> , 2018, 2, 1756-1764. | 5.2 | 53 |
| 31 | CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells. <i>Clinical Cancer Research</i> , 2015, 21, 2993-3002. | 7.0 | 52 |
| 32 | MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen. <i>Blood Advances</i> , 2019, 3, 83-95. | 5.2 | 51 |
| 33 | Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2019, 187, e45-e48. | 2.5 | 49 |
| 34 | Dasatinib-Induced Colitis after Allogeneic Stem Cell Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1900-1903. | 2.0 | 47 |
| 35 | Poxvirus Vectored Cytomegalovirus Vaccine to Prevent Cytomegalovirus Viremia in Transplant Recipients. <i>Annals of Internal Medicine</i> , 2020, 172, 306. | 3.9 | 45 |
| 36 | A fifty-year odyssey: prospects for a cytomegalovirus vaccine in transplant and congenital infection. <i>Expert Review of Vaccines</i> , 2018, 17, 889-911. | 4.4 | 42 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to <i>de novo</i> acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients. <i>Haematologica</i> , 2018, 103, 1662-1668. | 3.5 | 41 |
| 38 | Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation. <i>Blood Advances</i> , 2020, 4, 2073-2083. | 5.2 | 39 |
| 39 | Effect of antithymocyte globulin source on outcomes of bone marrow transplantation for severe aplastic anemia. <i>Haematologica</i> , 2017, 102, 1291-1298. | 3.5 | 38 |
| 40 | Influence of Absorption, Distribution, Metabolism, and Excretion Genomic Variants on Tacrolimus/Sirolimus Blood Levels and Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 268-276. | 2.0 | 36 |
| 41 | Long-Term Survival after Transplantation of Unrelated Donor Peripheral Blood or Bone Marrow Hematopoietic Cells for Hematologic Malignancy. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 55-59. | 2.0 | 34 |
| 42 | Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 599-634. | 4.9 | 33 |
| 43 | Outcome of Allogeneic Hematopoietic Cell Transplantation after Venetoclax and Hypomethylating Agent Therapy for Acute Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e322-e327. | 2.0 | 32 |
| 44 | Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors. <i>JAMA Oncology</i> , 2022, 8, 404. | 7.1 | 32 |
| 45 | Reduced intensity allogeneic hematopoietic stem cell transplantation for MDS using tacrolimus/sirolimus-based GVHD prophylaxis. <i>Leukemia Research</i> , 2012, 36, 1152-1156. | 0.8 | 31 |
| 46 | Improved Outcomes Using Tacrolimus/Sirolimus for Graft-versus-Host Disease Prophylaxis with a Reduced-Intensity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplant as treatment of Myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 281-286. | 2.0 | 29 |
| 47 | Posttransplant cyclophosphamide as GVHD prophylaxis for peripheral blood stem cell HLA-mismatched unrelated donor transplant. <i>Blood Advances</i> , 2021, 5, 2650-2659. | 5.2 | 29 |
| 48 | Venetoclax and hypomethylating agents in <sc><i>FLT3</i></sc>-mutated acute myeloid leukemia. <i>American Journal of Hematology</i> , 2020, 95, 1193-1199. | 4.1 | 28 |
| 49 | Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors. <i>Blood Advances</i> , 2021, 5, 975-983. | 5.2 | 27 |
| 50 | Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of <i>TP53</i> mutational status. <i>Haematologica</i> , 2017, 102, 2030-2038. | 3.5 | 26 |
| 51 | Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). <i>Blood Advances</i> , 2021, 5, 2481-2489. | 5.2 | 25 |
| 52 | A Phase I Study in Adults of Clofarabine Combined with High-Dose Melphalan as Reduced-Intensity Conditioning for Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 432-440. | 2.0 | 24 |
| 53 | Multicenter Biologic Assignment Trial Comparing Reduced-Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50 to 75 with Intermediate-2 and High-Risk Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network #1102 Study Rationale, Design, and Methods. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1566-1572. | 2.0 | 24 |
| 54 | Biomarker-guided preemption of steroid-refractory graft-versus-host disease with Î±-1-antitrypsin. <i>Blood Advances</i> , 2020, 4, 6098-6105. | 5.2 | 24 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. <i>Haematologica</i> , 2020, 105, 1329-1338. | 3.5 | 23 |
| 56 | Tissue-resident PSGL1loCD4+ T cells promote B cell differentiation and chronic graft-versus-host disease-associated autoimmunity. <i>Journal of Clinical Investigation</i> , 2021, 131, . | 8.2 | 21 |
| 57 | Conditional Survival, Cause-Specific Mortality, and Risk Factors of Late Mortality After Allogeneic Hematopoietic Cell Transplantation. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1153-1161. | 6.3 | 20 |
| 58 | Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: efficacy of hematopoietic stem cell transplantation. <i>Haematologica</i> , 2014, 99, 1868-1875. | 3.5 | 19 |
| 59 | Effect of isavuconazole on tacrolimus and sirolimus serum concentrations in allogeneic hematopoietic stem cell transplant patients: A drug-drug interaction study. <i>Transplant Infectious Disease</i> , 2019, 21, e13007. | 1.7 | 19 |
| 60 | Abnormal body composition is a predictor of adverse outcomes after autologous haematopoietic cell transplantation. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020, 11, 962-972. | 7.3 | 19 |
| 61 | Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1084-1090. | 2.0 | 19 |
| 62 | Tacrolimus/Sirolimus Vs. Tacrolimus/Methotrexate for Graft-Vs.-Host Disease Prophylaxis After HLA-Matched, Related Donor Hematopoietic Stem Cell Transplantation: Results of Blood and Marrow Transplant Clinical Trials Network Trial 0402. <i>Blood</i> , 2012, 120, 739-739. | 1.4 | 19 |
| 63 | Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. <i>Blood Advances</i> , 2020, 4, 3180-3190. | 5.2 | 18 |
| 64 | Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia. <i>Cancer</i> , 2022, 128, 529-535. | 4.1 | 17 |
| 65 | Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant. <i>Leukemia</i> , 2020, 34, 1898-1906. | 7.2 | 16 |
| 66 | Cytokine Release Syndrome Following Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 111.e1-111.e8. | 1.2 | 16 |
| 67 | Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1828-1835. | 2.0 | 15 |
| 68 | Ruxolitinib for the treatment of graft-versus-host disease. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 347-359. | 3.0 | 15 |
| 69 | The efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia with extramedullary involvement. <i>Leukemia and Lymphoma</i> , 2020, 61, 2020-2023. | 1.3 | 15 |
| 70 | Atrial Fibrillation in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2021, 39, 902-910. | 1.6 | 15 |
| 71 | Management of Drug Interaction between Posaconazole and Sirolimus in Patients Who Undergo Hematopoietic Stem Cell Transplant. <i>Pharmacotherapy</i> , 2015, 35, 578-585. | 2.6 | 14 |
| 72 | Comparison of outcomes of HCT in blast phase of <i>t(9;22) BCR-ABL1</i> MPN with de novo AML and with AML following MDS. <i>Blood Advances</i> , 2020, 4, 4748-4757. | 5.2 | 14 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2139-2146. | 2.0 | 14 |
| 74 | Acute GVHD Diagnosis and Adjudication in a Multicenter Trial: A Report From the BMT CTN 1202 Biorepository Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 1878-1887. | 1.6 | 14 |
| 75 | Remission Induction in a Phase I/II Study of an Anti-CD20-Interleukin-2 Immunocytokine DL-Leu16-IL2 in Patients with Relapsed B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 1533-1533. | 1.4 | 14 |
| 76 | Long-Term Outcomes of Patients with Acute Myelogenous Leukemia Treated with Myeloablative Fractionated Total Body Irradiation TBI-Based Conditioning with a Tacrolimus- and Sirolimus-Based Graft-versus-Host Disease Prophylaxis Regimen: 6-Year Follow-Up from a Single Center. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 292-299. | 2.0 | 13 |
| 77 | Pulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosis. <i>Bone Marrow Transplantation</i> , 2020, 55, 877-883. | 2.4 | 13 |
| 78 | Feasibility and Acceptability of Using a Telehealth Platform to Monitor Cardiovascular Risk Factors in Hematopoietic Cell Transplantation Survivors at Risk for Cardiovascular Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1233-1237. | 2.0 | 13 |
| 79 | Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study. <i>Blood Advances</i> , 2022, 6, 1444-1453. | 5.2 | 13 |
| 80 | Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: considerations for evidence-based GVHD prophylaxis. <i>Expert Review of Hematology</i> , 2014, 7, 407-421. | 2.2 | 12 |
| 81 | Allogeneic Hematopoietic Cell Transplantation Outcomes in Patients Carrying Isocitrate Dehydrogenase Mutations. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e400-e405. | 0.4 | 12 |
| 82 | Rapid Acquisition of Cytomegalovirus-Specific T Cells with a Differentiated Phenotype, in Nonviremic Hematopoietic Stem Transplant Recipients Vaccinated with CMVPepVax. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 771-784. | 2.0 | 12 |
| 83 | A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102. <i>Blood</i> , 2020, 136, 19-21. | 1.4 | 12 |
| 84 | Philadelphia chromosome as a recurrent event among therapy-related acute leukemia. <i>American Journal of Hematology</i> , 2017, 92, E18-E19. | 4.1 | 11 |
| 85 | RBC and platelet transfusion support in the first 30 and 100 days after haploidentical hematopoietic stem cell transplantation. <i>Transfusion</i> , 2019, 59, 3371-3385. | 1.6 | 11 |
| 86 | Favorable outcomes for allogeneic hematopoietic cell transplantation in elderly patients with NPM1-mutated and FLT3-ITD-negative acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2020, 55, 473-475. | 2.4 | 11 |
| 87 | Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 921.e1-921.e10. | 1.2 | 11 |
| 88 | Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (<sc>HMA</sc> or liposomal daunorubicin-cytarabine (<sc>CPX</sc>). <i>American Journal of Hematology</i> , 2021, 96, E196-E200. | 4.1 | 10 |
| 89 | Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host Disease. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 988.e1-988.e7. | 1.2 | 10 |
| 90 | The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis. <i>Haematologica</i> , 2023, 108, 150-160. | 3.5 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Influence of donor KIR genotypes on reduced relapse risk in acute myelogenous leukemia after hematopoietic stem cell transplantation in patients with CMV reactivation. <i>Leukemia Research</i> , 2019, 87, 106230. | 0.8 | 9 |
| 92 | Red blood cell and platelet transfusion support in the first 30 and 100 days after allogeneic hematopoietic cell transplant. <i>Transfusion</i> , 2020, 60, 2225-2242. | 1.6 | 9 |
| 93 | Long-term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation From Unrelated Donor Using Tacrolimus/Sirolimus-based GvHD Prophylaxis: Impact of HLA Mismatch. <i>Transplantation</i> , 2020, 104, 1070-1080. | 1.0 | 9 |
| 94 | Explainable Tree-Based Predictions for Unplanned 30-Day Readmission of Patients With Cancer Using Clinical Embeddings. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 155-167. | 2.1 | 9 |
| 95 | Large-scale manufacturing and characterization of CMV-CD19CAR T cells. , 2022, 10, e003461. | | 9 |
| 96 | Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide. <i>Blood Advances</i> , 2022, 6, 4098-4106. | 5.2 | 9 |
| 97 | Outcome of Second Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 519-522. | 0.4 | 8 |
| 98 | Use of high-dose mesna and hyperhydration leads to lower incidence of hemorrhagic cystitis after posttransplant cyclophosphamide-based allogeneic transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2464-2470. | 2.4 | 8 |
| 99 | Post-Allogeneic Hematopoietic Stem Cell Transplantation Eculizumab as Prophylaxis Against Hemolysis and Thrombosis for Patients with Hematologic Disorders Associated with Paroxysmal Nocturnal Hemoglobinuria Clones. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e183-e185. | 2.0 | 7 |
| 100 | Severe Acute Respiratory Syndrome Coronavirus 2-Specific Monoclonal Antibody for the Treatment of Mild to Moderate Coronavirus Disease 2019 in Cancer Patients: A Single-Center Experience. <i>Journal of Infectious Diseases</i> , 2022, 225, 352-354. | 4.0 | 7 |
| 101 | Phase I Study of Yttrium-90 Labeled ANTI-CD25 (aTac) Monoclonal Antibody PLUS BEAM for Autologous Hematopoietic CELL Transplantation (AHCT) in Patients with Mature T-CELL NON-Hodgkin Lymphoma, the "a-TAC-BEAM Regimen". <i>Blood</i> , 2018, 132, 611-611. | 1.4 | 7 |
| 102 | Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL. <i>Blood Advances</i> , 2022, 6, 4936-4948. | 5.2 | 7 |
| 103 | Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 287-292. | 2.0 | 6 |
| 104 | Protective effect of HLA-DPB1 mismatch remains valid in reduced-intensity conditioning unrelated donor hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 409-418. | 2.4 | 6 |
| 105 | Iron Overload Is Associated with Delayed Engraftment and Increased Nonrelapse Mortality in Recipients of Umbilical Cord Blood Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1697-1703. | 2.0 | 6 |
| 106 | Prediction of Acute Graft versus Host Disease and Relapse by Endogenous Metabolomic Compounds in Patients Receiving Personalized Busulfan-Based Conditioning. <i>Journal of Proteome Research</i> , 2021, 20, 684-694. | 3.7 | 6 |
| 107 | Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage Therapies. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 255.e1-255.e9. | 1.2 | 6 |
| 108 | Late-occurring infections in a contemporary cohort of hematopoietic cell transplantation survivors. <i>Cancer Medicine</i> , 2021, 10, 2956-2966. | 2.8 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Development of CMV-CD19 bi-specific CAR T cells with post-infusion in vivo boost using an anti-CMV vaccine. <i>International Journal of Hematology</i> , 2021, 114, 544-553. | 1.6 | 6 |
| 110 | Pharmacometabonomic association of cyclophosphamide 4- β -hydroxylation in hematopoietic cell transplant recipients. <i>Clinical and Translational Science</i> , 2022, 15, 1215-1224. | 3.1 | 6 |
| 111 | Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2022, 196, . | 2.5 | 6 |
| 112 | Efficacy of low-dose zoster prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 1662-1664. | 2.4 | 5 |
| 113 | Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-versus-Host Disease Prophylaxis in Patients with Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1425-1432. | 2.0 | 5 |
| 114 | A Machine-Learning Sepsis Prediction Model for Patients Undergoing Hematopoietic Cell Transplantation. <i>Blood</i> , 2018, 132, 711-711. | 1.4 | 5 |
| 115 | Successful outcome of pre-engraftment COVID-19 in an HCT patient: impact of targeted therapies and cellular immunity. <i>Blood Advances</i> , 2022, 6, 1645-1650. | 5.2 | 5 |
| 116 | Detection and preliminary characterization of CD8 ⁺ T lymphocytes specific for Wilms's tumor antigen in patients with non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 2490-2499. | 1.3 | 4 |
| 117 | Ex vivo detection of CD8 T cells specific for H-Y minor histocompatibility antigens in allogeneic hematopoietic stem cell transplant recipients. <i>Transplant Immunology</i> , 2014, 30, 128-135. | 1.2 | 4 |
| 118 | Efficacy of blinatumomab for MRD relapse in ALL post allogenic HCT. <i>Leukemia Research</i> , 2021, 104, 106579. | 0.8 | 4 |
| 119 | Peri-Transplant Administration of Ruxolitinib Is Safe and Feasible in Patients with Myelofibrosis: Primary Results of a Pilot Open-Label Study of Ruxolitinib Administration in Combination with Reduced Intensity Conditioning. <i>Blood</i> , 2019, 134, 669-669. | 1.4 | 4 |
| 120 | Effect of the Terminal Complement Inhibitor Eculizumab on Patient Reported Outcomes in Paroxysmal Nocturnal Hemoglobinuria (PNH): Phase III Triumph Study Results.. <i>Blood</i> , 2006, 108, 3770-3770. | 1.4 | 4 |
| 121 | High prevalence and inferior long-term outcomes for TP53 mutations in therapy-related acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2022, 97, . | 4.1 | 4 |
| 122 | Total Marrow and Lymphoid Irradiation with Post-Transplantation Cyclophosphamide for Patients with AML in Remission. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 368.e1-368.e7. | 1.2 | 4 |
| 123 | Clinical and immunologic responses to extracorporeal photopheresis and low-dose IL-2 in patients with steroid refractory chronic graft-versus host disease. <i>Bone Marrow Transplantation</i> , 2022, 57, 1045-1047. | 2.4 | 4 |
| 124 | A Phase II Trial of Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis in HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S188. | 2.0 | 3 |
| 125 | Priorities for Improving Outcomes for Nonmalignant Blood Diseases: A Report from the Blood and Marrow Transplant Clinical Trials Network. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e94-e100. | 2.0 | 3 |
| 126 | Impact of Genetic Mutations on the Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia with Antecedent Myeloproliferative Neoplasm. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S12. | 2.0 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | Superior Outcomes with Fludarabine-Busulfan (Flu/Bu) Based Conditioning for Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis - a Comparative Analysis By CIBMTR. <i>Blood</i> , 2021, 138, 912-912. | 1.4 | 3 |
| 128 | Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 187.e1-187.e10. | 1.2 | 3 |
| 129 | Association Between Body Composition and Development of Glucose Intolerance after Allogeneic Hematopoietic Cell Transplantation. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 2004-2010. | 2.5 | 3 |
| 130 | Cytokine gene polymorphisms are associated with response to blinatumomab in Bâ€œcell acute lymphoblastic leukemia. <i>European Journal of Haematology</i> , 2021, 106, 851-858. | 2.2 | 2 |
| 131 | Late and very late relapsed acute lymphoblastic leukemia: clinical and molecular features, and treatment outcomes. <i>Blood Cancer Journal</i> , 2021, 11, 125. | 6.2 | 2 |
| 132 | Clinical Outcomes of Patients with Secondary Acute Myeloid Leukemia (sAML) Treated with Hypomethylating Agent Plus Venetoclax (HMA-Ven) or Liposomal Daunorubicin Cytarabine (CPX-351). <i>Blood</i> , 2020, 136, 37-38. | 1.4 | 2 |
| 133 | Efficacy of Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Peripheral Blood Stem Cell HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation; A Prospective Pilot Trial. <i>Blood</i> , 2020, 136, 49-50. | 1.4 | 2 |
| 134 | Improved Outcome After Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation (RI-HCT) for Myelodysplastic Syndrome (MDS) Using Tacrolimus/Sirolimus-Based Gvhd Prophylaxis.. <i>Blood</i> , 2009, 114, 2771-2771. | 1.4 | 2 |
| 135 | Current Management and New Developments in the Treatment of Myelodysplastic Syndrome. <i>Cancer Treatment and Research</i> , 2021, 181, 115-132. | 0.5 | 2 |
| 136 | The Use of Sirolimus Combined with Tacrolimus and Low-Dose Methotrexate Is Effective in Preventing Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2006, 108, 2866-2866. | 1.4 | 2 |
| 137 | Outcomes of Venetoclax and Hypomethylating Agents (HMA) in Adult Patients with KMT2A-Rearranged Leukemias. <i>Blood</i> , 2021, 138, 3430-3430. | 1.4 | 2 |
| 138 | Tacrolimus initial steady state level in post-transplant cyclophosphamide-based GvHD prophylaxis regimens. <i>Bone Marrow Transplantation</i> , 2021, , . | 2.4 | 2 |
| 139 | Successful treatment of refractory pure red cell aplasia in major ABO-mismatched allogeneic hematopoietic stem cell transplant with single agent Ibrutinib. <i>Bone Marrow Transplantation</i> , 2022, 57, 830-833. | 2.4 | 2 |
| 140 | Long-term follow-up of patients with poor-risk acute leukemia treated on a phase 2 trial undergoing intensified conditioning regimen prior to allogeneic hematopoietic cell transplantation. <i>Leukemia and Lymphoma</i> , 2022, 63, 1220-1226. | 1.3 | 2 |
| 141 | Technology-enabled activation of skin cancer screening for hematopoietic cell transplantation survivors and their primary care providers (TEACH). <i>BMC Cancer</i> , 2020, 20, 721. | 2.6 | 1 |
| 142 | Cost analysis of ganciclovir and foscarnet in recipients of allogeneic hematopoietic cell transplant with cytomegalovirus viremia. <i>Transplant Infectious Disease</i> , 2020, 22, e13233. | 1.7 | 1 |
| 143 | Decision Analysis of Transplantation for Patients with Myelodysplasia: â€œWho Should We Transplant Today?â€• <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 305-315. | 2.3 | 1 |
| 144 | Incidence and Risk Factors for De Novo Cutaneous Squamous Cell Carcinoma in a Contemporary Cohort of Long-Term Hematopoietic Cell Transplantation Survivors. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2073-2076.e5. | 0.7 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 145 | Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Flurabine Improves Transplant Outcomes in Older MDS Patients. <i>Blood</i> , 2019, 134, 253-253. | 1.4 | 1 |
| 146 | Optimization of Tacrolimus Serum Levels When Combined with Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Hematopoietic Cell Transplantation: Outcome Data Analysis. <i>Blood</i> , 2019, 134, 4518-4518. | 1.4 | 1 |
| 147 | Large-Scale Manufacturing of CMV-CD19CAR T Cells and Characterization of Their Biologic and Immunologic Properties. <i>Blood</i> , 2019, 134, 3247-3247. | 1.4 | 1 |
| 148 | Chemokine Receptor Gene Polymorphisms and Severity of Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation from Sibling Donors.. <i>Blood</i> , 2007, 110, 4989-4989. | 1.4 | 1 |
| 149 | Thrombotic Microangiopathy with Tacrolimus/Sirolimus-Based GVHD Prophylaxis Regimen in Patients Undergoing Hematopoietic Stem Cell Transplant from a Matched Unrelated Donor. <i>Blood</i> , 2008, 112, 797-797. | 1.4 | 1 |
| 150 | Final Report of a Phase I Study of Clofarabine Plus High Dose Melphalan as a Conditioning Regimen for Allogeneic Transplantation. <i>Blood</i> , 2010, 116, 528-528. | 1.4 | 1 |
| 151 | Incidence and Risk Factors of CMV Reactivation after Haploidentical Hematopoietic Cell Transplantation Using High-Dose Post-Transplant Cyclophosphamide - Possible Role of Donor KIR Genotypes. <i>Blood</i> , 2018, 132, 3416-3416. | 1.4 | 1 |
| 152 | Updated Analysis: Novel Machine-Learning-Based Sepsis Prediction Model for Patients Undergoing Hematopoietic Stem Cell Transplantation (Early Sepsis Prediction/Identification for Transplant) <i>TJ ETQq0 0 0 rgBT /Overlock 10 Tf 50 45</i> | | |
| 153 | A Randomized Open Label Pilot Study of <i>Clostridium Butyricum</i> Miyairi 588 (CBM588) in Recipients of Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2021, 138, 334-334. | 1.4 | 1 |
| 154 | Social Vulnerability Is a Clinically Important Predictor of Outcomes after Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2021, 138, 842-842. | 1.4 | 1 |
| 155 | Younger HLA-Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (allo-HCT) for Myelodysplastic Syndromes (MDS) Is Associated with Superior Disease-Free Survival Compared to Older HLA-Identical Sibling Donors: CIBMTR Analysis. <i>Blood</i> , 2020, 136, 43-44. | 1.4 | 1 |
| 156 | Retention of Donor T Cells in Lymphohematopoietic Tissue and Augmentation of Tissue PD-L1 Protection for Prevention of GVHD While Preserving GVL Activity. <i>Frontiers in Immunology</i> , 2022, 13, . | 4.8 | 1 |
| 157 | Response: A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 different conditioning regimens. <i>Blood</i> , 2010, 115, 4317-4317. | 1.4 | 0 |
| 158 | Cytomegalovirus Infections Following Reduced-Intensity Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2004, 104, 2245-2245. | 1.4 | 0 |
| 159 | Reduced Intensity (RI) Allogeneic Hematopoietic Cell Transplantation (HCT) Improves Outcomes for Older (≥ 60 Yrs) Patients (Pts) with Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2007, 110, 1089-1089. | 1.4 | 0 |
| 160 | Impact of Donor Serostatus on CMV Reactivation and Reconstitution of Multi-Function CMV-Specific T Cells in CMV-Positive Transplant Recipients. <i>Blood</i> , 2008, 112, 4339-4339. | 1.4 | 0 |
| 161 | A Retrospective Analysis of Using Pre-Transplant Functional FDG-PET to Predict for Relapse and Survival in Relapsed Hodgkin Lymphoma (HL) Patients Undergoing Autologous Hematopoietic Cell Transplantation (AHCT).. <i>Blood</i> , 2009, 114, 1225-1225. | 1.4 | 0 |
| 162 | Fludarabine-Based Conditioning for Allogeneic Marrow Transplantation From Unrelated Donors in Severe Aplastic Anemia (SAA): Serious and Unexpected Adverse Events in Pre-Defined Cyclophosphamide (CY) Dose Levels. <i>Blood</i> , 2011, 118, 3009-3009. | 1.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 163 | Detection and Characterization of Antigen-Driven CD8+ T Lymphocytes Specific for Wilms' Tumor Antigen in Patients with Non-Hodgkin Lymphoma. <i>Blood</i> , 2011, 118, 953-953. | 1.4 | 0 |
| 164 | Transplantation For Myelodysplastic Syndrome Evolving From Aplastic Anemia Treated With Immunosuppressive Therapy: From The Fred Hutchinson Cancer Research Center and Center For International Bone Marrow Transplantation Research. <i>Blood</i> , 2013, 122, 924-924. | 1.4 | 0 |
| 165 | Incidence and Predictors of Late-Occurring Central Nervous System Complications in Allogeneic Hematopoietic Cell Transplant Survivors. <i>Blood</i> , 2016, 128, 5799-5799. | 1.4 | 0 |
| 166 | MIPSS70+ V2.0 and Revised Cytogenetics Changes Predict Outcomes of Allogeneic Transplantation with Fludarabine and Melphalan Conditioning in Patients with Myelofibrosis. <i>Blood</i> , 2018, 132, 1752-1752. | 1.4 | 0 |
| 167 | Serial Biomarker Monitoring Early after HCT Identifies Different Risks for Relapse and Graft-Vs-Host Disease. <i>Blood</i> , 2018, 132, 356-356. | 1.4 | 0 |
| 168 | Cytokine Gene Polymorphisms Are Associated with Disease Response to Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 1549-1549. | 1.4 | 0 |
| 169 | Effect of Vancomycin-Resistance Enterococci Colonization Status Prior to Allogeneic Hematopoietic Cell Transplantation on Transplant Outcomes: A Single Center Retrospective Experience. <i>Blood</i> , 2018, 132, 3386-3386. | 1.4 | 0 |
| 170 | Muscle Depletion Is an Important and Clinically Relevant Predictor of Outcomes after Autologous Hematopoietic Cell Transplantation. <i>Blood</i> , 2018, 132, 620-620. | 1.4 | 0 |
| 171 | Clinical Outcomes of MDS Patients Who Were Allogeneic Hematopoietic Stem Cell Transplant Candidates but Did Not Proceed with Transplantation. <i>Blood</i> , 2018, 132, 2181-2181. | 1.4 | 0 |
| 172 | Use of Monoclonal Antibody Therapy in Hematologic Patients with Mild-to-Moderate COVID-19: A Retrospective Single-Center Experience. <i>Blood</i> , 2021, 138, 3037-3037. | 1.4 | 0 |
| 173 | The Impact of Somatic Mutations on Allogeneic Hematopoietic Cell Transplantation in Chronic Myelomonocytic Leukemia: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis. <i>Blood</i> , 2021, 138, 417-417. | 1.4 | 0 |
| 174 | Prognostic Value of Elafin in Acute Graft-Versus-Host Disease. <i>Blood</i> , 2021, 138, 3900-3900. | 1.4 | 0 |
| 175 | Prediction of Graft-Versus-Host Disease in Recipients of Single Mismatched Unrelated Hematopoietic Cell Transplantation Donor Using a Highly Multiplexed Proteomic Assay, MHC-Pepseq. <i>Blood</i> , 2021, 138, 1808-1808. | 1.4 | 0 |
| 176 | Outcomes of Allogeneic Hematopoietic Cell Transplantation in Adults with Ph-like ALL. <i>Blood</i> , 2021, 138, 3955-3955. | 1.4 | 0 |
| 177 | A Phase II Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy of Cmvpepvax for Preventing CMV Reactivation/Disease after Matched Related/Unrelated Donor Hematopoietic Cell Transplant. <i>Blood</i> , 2021, 138, 2887-2887. | 1.4 | 0 |
| 178 | The Impact of Letermovir (LTV) Prophylaxis on Early Cytomegalovirus Infection (CMVi) and Outcomes in the Adult Allogeneic Hematopoietic Cell Transplantation (alloHCT) Recipients with High-Risk Donor Type. <i>Blood</i> , 2021, 138, 1776-1776. | 1.4 | 0 |
| 179 | Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in T-Cell Prolymphocytic Leukemia (T-PLL): An Analysis from the CIBMTR. <i>Blood</i> , 2020, 136, 28-29. | 1.4 | 0 |
| 180 | Alternative Donor Hematopoietic Cell Transplantation for Pediatric, Adolescent and Young Adult with Hematological Diseases. <i>Blood</i> , 2020, 136, 5-6. | 1.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 181 | Vaccination of Hematopoietic Stem Cell (HCT) Donors with Triplex, a Novel Cytomegalovirus Vaccine: Safety, Feasibility and Adoptive Transfer of Protective CMV-Specific T Cells in HCT Recipients. Blood, 2020, 136, 33-33. | 1.4 | 0 |
| 182 | Hemorrhagic Cystitis in Patients Undergoing Allogeneic Hematopoietic Cell Transplant with Post Transplant Cyclophosphamide As GvHD Prophylaxis. Blood, 2020, 136, 21-22. | 1.4 | 0 |
| 183 | Clinical Impact of Cytokine Release Syndrome on Outcomes of Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide. Blood, 2020, 136, 10-11. | 1.4 | 0 |
| 184 | Healthcare Resource Utilization in Transplant Patients Who Are at a Higher-Risk to Develop Cytomegalovirus Infection during Their Primary Transplant-Related Hospitalization. Blood, 2020, 136, 16-17. | 1.4 | 0 |
| 185 | Phase I Study of Yttrium-90 Labeled ANTI-CD25 (aTac) Monoclonal Antibody PLUS BEAM for Autologous Hematopoietic Cell Transplantation (AHCT) in Patients with Mature T-Cell NON-Hodgkin Lymphoma, the "a-TAC-BEAM Regimen". Blood, 2020, 136, 10-11. | 1.4 | 0 |